A 4D Molecular Therapeutics, Inc. phase 2 PRISM study indicated that there was an 89% reduction in annualized injections when Wet-AMD patients were given a high dose of 4D-150; Phase 3 trial ...

SAN FRANCISCO--(BUSINESS WIRE)--4D Molecular Therapeutics (4DMT), a leader in next-generation gene therapy vector discovery and product development, today announced a collaboration and license ...

TOKYO and EMERYVILLE, Calif., July 10, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) (President and CEO: Naoki Okamura, "Astellas") and 4D Molecular Therapeutics, Inc. (FDMT) (CEO: David Kirn, ...

EMERYVILLE, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene ...

EMERYVILLE, CA--(Marketwired - January 07, 2016) - 4D Molecular Therapeutics (4DMT), a leader in Adeno-Associated Virus (AAV) gene therapy vector discovery and product development, today announced ...

Please provide your email address to receive an email when new articles are posted on . Astellas has gained the rights to utilize 4DMT’s R100 vector to deliver its unique genetic payloads. Astellas is ...

On Monday, 4D Molecular Therapeutics (NASDAQ:FDMT) shares saw its price target significantly raised by investment firm Jefferies, from $30.00 to $58.00, while the firm maintained its Buy rating. The ...

EMERYVILLE, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (4DMT) (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for ...

TOKYO and EMERYVILLE, Calif., July 10, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) (President and CEO: Naoki Okamura, "Astellas") and 4D Molecular ...

Astellas Pharma Inc. and 4D Molecular Therapeutics, Inc. announced a license agreement under which Astellas gains rights to utilize the intravitreal retinotropic R100 vector invented by 4DMT for one ...